Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas
- PMID: 18284804
- DOI: 10.1185/030079908x280419
Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas
Abstract
Background: Atopic dermatitis (AD) is a common, chronic skin disorder characterized by itch and dry skin, which can develop into pruritic red plaques that ooze when scratched. AD flares often occur in anatomic areas where the skin is naturally thin (the face, neck, and intertriginous zones). Such regions, especially the face, are also areas of sensitive skin and need special consideration when being treated.
Objective: This article will briefly review the concepts of thin and sensitive skin and discuss the treatment of AD in such areas.
Methods: The MEDLINE database was searched for English-language articles published that contained the text terms atopic dermatitis, sensitive skin, treatment, topical corticosteroids, or topical calcineurin inhibitors. Articles that pertained to the safety and efficacy of various treatments were selected for further review.
Results: Topical corticosteroids (TCSs) are effective for the treatment of AD in thin and sensitive skin areas, but their use is limited due to adverse events, such as skin thinning, and the potential for impairing the skin barrier. Topical calcineurin inhibitors (TCIs) also provide effective AD treatment without impairing the skin barrier or inducing skin thinning. Although TCIs may be associated with a higher incidence of application-site reactions such as pruritus and skin burning, these symptoms are typically transient and mild to moderate in nature.
Limitations: This analysis focused primarily on relatively recent key trials evaluating the treatment of AD in sensitive skin; due to the limited number of controlled trials evaluating TCS agents, consensus statements and comprehensive review articles were used for most of the information pertaining to this therapeutic option.
Conclusions: Although both TCSs and TCIs have a place in a long-term, comprehensive treatment strategy for AD, TCIs may have a particular use in thin and sensitive skin areas.
Similar articles
-
Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.Clin Ther. 2006 Dec;28(12):1972-82. doi: 10.1016/j.clinthera.2006.12.014. Clin Ther. 2006. PMID: 17296454 Review.
-
Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption.Am J Ther. 2009 May-Jun;16(3):264-73. doi: 10.1097/MJT.0b013e31818a975c. Am J Ther. 2009. PMID: 19262357 Review.
-
The role of topical calcineurin inhibitors in atopic dermatitis.Br J Dermatol. 2004 Dec;151 Suppl 70 Dec 2004:3-27. doi: 10.1111/j.1365-2133.2004.06269.x. Br J Dermatol. 2004. PMID: 15548171 Review.
-
How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?J Invest Dermatol. 2016 Oct;136(10):1944-1949. doi: 10.1016/j.jid.2016.05.104. Epub 2016 Jun 2. J Invest Dermatol. 2016. PMID: 27265005
-
Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.Am J Clin Dermatol. 2011 Feb 1;12(1):15-24. doi: 10.2165/11319300-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21067248 Review.
Cited by
-
Topical calcineurin inhibitors in systemic lupus erythematosus.Ther Clin Risk Manag. 2010 Apr 15;6:95-101. doi: 10.2147/tcrm.s3193. Ther Clin Risk Manag. 2010. PMID: 20421909 Free PMC article.
-
Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.J Am Acad Dermatol. 2014 Jul;71(1):116-32. doi: 10.1016/j.jaad.2014.03.023. Epub 2014 May 9. J Am Acad Dermatol. 2014. PMID: 24813302 Free PMC article.
-
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?Clin Rev Allergy Immunol. 2016 Dec;51(3):263-292. doi: 10.1007/s12016-015-8488-5. Clin Rev Allergy Immunol. 2016. PMID: 25931325 Review.
-
Childhood atopic dermatitis: current developments, treatment approaches, and future expectations.Turk J Med Sci. 2019 Aug 8;49(4):963-984. doi: 10.3906/sag-1810-105. Turk J Med Sci. 2019. PMID: 31408293 Free PMC article.
-
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.Dermatol Ther (Heidelb). 2023 Sep;13(9):1987-2000. doi: 10.1007/s13555-023-00960-w. Epub 2023 Jul 22. Dermatol Ther (Heidelb). 2023. PMID: 37480432 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials